A Case of Autoimmune Neutropenia That Responded to Rituximab

Area of Science:

• Hematology
• Immunology
• Internal Medicine

Background:

• Autoimmune neutropenia (AIN) is an immune-mediated condition causing neutrophil destruction, affecting fewer than 1 in 100,000 individuals annually.
• Standard AIN treatment includes supportive care with granulocyte colony-stimulating factor (G-CSF) and antibiotics for infections.
• Immunomodulatory therapies like steroids, IVIG, and rituximab are less established, though rituximab shows recent promise.

Observation:

• A 76-year-old male patient presented with antineutrophil antibody-negative AIN and concurrent immune thrombocytopenic purpura (ITP).
• Initial treatment with G-CSF provided only temporary improvement in neutrophil counts.
• Subsequent treatment with rituximab resulted in a sustained remission of AIN.

Findings:

• Rituximab demonstrated efficacy in inducing a lasting remission for autoimmune neutropenia in this patient.
• This case highlights rituximab as a potential therapeutic option for AIN, particularly when standard treatments are insufficient.
• The patient's concurrent ITP also warrants consideration in the overall management strategy.

Implications:

• Rituximab may represent a valuable therapeutic strategy for refractory autoimmune neutropenia, offering sustained disease control.
• Further clinical investigation into rituximab's role in AIN management is warranted, especially in cases refractory to G-CSF.
• This case contributes to the limited literature on rituximab for AIN, emphasizing its potential in complex hematological presentations.